Paper Details

  1. Home
  2. Paper Details

Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study.

Author: JoungBoyoung, ParkHojun, ParkRae Woong, ParkSooyoung, YoonDukyong, YouSeng Chan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

Olmesartan, an angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. This study investigated the association between olmesartan and other ARBs and the incidence of enteropathy in Korea.
Paper Details　
Original Abstract of the Article :
Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of enteropathy in Korea...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325440/

データ提供：米国国立医学図書館（NLM）

Olmesartan and Enteropathy: Addressing Concerns

Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. This study investigates the association between olmesartan and other ARBs and the incidence of enteropathy, specifically focusing on the Korean population. This research is crucial for understanding the potential risks and safety profile of olmesartan, a widely used medication.

No Association Found: Reassuring Results

The study found no association between olmesartan and the risk of enteropathy in a Korean nationwide observational cohort study. This finding provides reassurance regarding the safety of olmesartan in this population, potentially allaying concerns raised by previous reports.

Understanding Drug Safety: A Continuous Process

This research underscores the importance of ongoing surveillance and monitoring of drug safety. While olmesartan appears to be safe in the Korean population, further research is needed to confirm this finding and understand potential variations in drug response across different populations.

Dr.Camel's Conclusion

Think of the desert as a place of vast and diverse landscapes, each with its unique challenges. Just as a camel must adapt to different terrains, so too must we understand the potential variations in drug response across different populations. This study provides valuable insights into the safety profile of olmesartan, reminding us that the quest for understanding drug safety is a continuous journey, requiring ongoing research and vigilance.
Date :
  1. Date Completed 2020-01-29
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

29172402

DOI: Digital Object Identifier

PMC6325440

Related Literature

Article Analysis
・Side Effects of olmesartan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.